MedTrace Logo

Study Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers

NCT01554293 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2013-05-16

No results posted yet for this study

Summary

PBL 1427 is a Dipeptidyl peptidase (DPP)-IV inhibitor being developed for treatment of type 2 diabetes. Although a number of DPP-IV inhibitors have been described, there still exists a need for new DPP-IV inhibitors that have better half-life, advantageous potency, stability and selectivity, less toxicity and/or better pharmacodynamic properties.

Conditions

Interventions

DRUG

Matching placebo

Matching Placebo, single dose

DRUG

PBL 1427 capsules

PBL 1427 capsules 20 mg and 150 mg, single dose

Sponsors & Collaborators

  • Panacea Biotec Ltd

    lead INDUSTRY

Principal Investigators

  • Dr Deepak C Chilkoti · Head-Clinical Operations

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-07-31
Completion
2013-09-30

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01554293 on ClinicalTrials.gov